Month: October 2022

On April 22, 2004, Taveras, Arthur G.; Chao, Jianhua; Biju, Purakkattle J.; Yu, Younong; Fine, Jay S.; Hipkin, William; Aki, Cynthia J.; Merritt, J. Robert; Li, Ge; Baldwin, John J.; Lai, Gaifa; Wu, Minglang; Hecker, Evan A. published a patent.Computed Properties of 74904-29-3 The title of the patent was Preparation of diaminothiadiazole dioxides and monoxides as CXC- and CC-chemokine receptor ligands. And the patent contained the following:

Disclosed are diaminothiadiazole mono- and dioxides (shown as I; e.g. II) and the pharmaceutically acceptable salts and solvates thereof. Examples of substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino; examples of substituent B include aryl and heteroaryl; g = 1, 2. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenesis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using I. Although the methods of preparation are not claimed, hundreds of example preparations and/or characterization data are included. For example, II was prepared in 31% yield from the 4-methoxy analog and isopropylamine in the presence of DIEA in MeOH; the 4-methoxy analog was prepared from the dimethoxy analog and N,N-dimethyl-3-amino-2-hydroxybenzamide in 99% crude yield. Antagonist activities of some examples of I towards CXCR1, CXCR2 and CCR7 are given. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Computed Properties of 74904-29-3

The Article related to aminothiadiazole oxide dioxide preparation chemokine receptor antagonist, thiadiazole diamino oxide dioxide preparation chemokine receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Computed Properties of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 21, 2005, Biju, Purakkattle J.; Taveras, Arthur G.; Yu, Younong; Zheng, Junying; Chao, Jianhua; Aki, Cynthia J.; Fine, Jay; Lundell, Daniel; Priestley, Tony; Reggiani, Angelo; Merritt, J. Robert; Baldwin, John J. published a patent.Formula: C10H11NO2 The title of the patent was Preparation of diaminothiadiazoles as CXC- and CC-chemokine receptor ligands. And the patent contained the following:

Disclosed are diaminothiadiazoles I [A = (hetero)aryl, (hetero)arylmethyl (substituted at CH2), etc.; B = (hetero)aryl] and the pharmaceutically acceptable salts and solvates thereof. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenesis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using I. Although the methods of preparation are not claimed, hundreds of example preparations and/or characterization data are included. For example, II was prepared in 43% yield from its monooxide III (preparation given). Antagonist activities of some examples of I towards CXCR1, CXCR2 and CCR7 are given. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Formula: C10H11NO2

The Article related to aminothiadiazole preparation chemokine receptor antagonist cxcr1 cxcr2 ccr7, thiadiazole diamino preparation chemokine receptor antagonist cxcr1 cxcr2 ccr7, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Formula: C10H11NO2

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On June 7, 2022, Tang, Feng; Li, Zhen; Zhang, Guobao; Zhou, Feng; Chen, Ping; Ren, Jinsheng published a patent.Product Details of 58142-46-4 The title of the patent was Preparation of (piperazinyl)tetrahydropyridopyrimidine derivatives and application for treating KRAS G12C mutant tumors. And the patent contained the following:

The present invention relates to the preparation of (piperazinyl)tetrahydropyridopyrimidine derivatives and uses thereof. In particular, (piperazinyl)tetrahydropyridopyrimidine derivatives I (R is -C(R6)=CH(R7), furanyl, -CH(F)(Cl), etc.; Q is selected from C=O or S(=O)2; R1 is selected from heterocyclyl or NR4R5; R2 is selected from aryl or heteroaryl; R3 is selected from hydrogen or NC-CH2; R4 and R5 are independently selected from hydrogen, alkyl, aryl or heteroaryl, alkylacyl, C1-4 alkyloxyacyl, or R4 and R5 together with the nitrogen atom to which they are attached form a heterocyclyl; R6 is selected from hydrogen or fluorine; R7 is selected from hydrogen, halogen, C1-4 alkyl or C1-4 alkoxy, described C1-4 alkyl or C1-4 alkoxy is optionally by =O, halogen, C1-4 alkoxy, etc.; n is selected from 0, 1, 2; m is selected from 1, 2, 3) were prepared The inventive compounds or a pharmaceutically acceptable salts, pharmaceutical compositions are used in preparation of medicaments for preventing and/or treating KRAS G12C mutant tumors. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Product Details of 58142-46-4

The Article related to piperazinyl tetrahydropyridopyrimidine preparation antitumor agent, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On September 1, 2020, Yu, Xiyong; Lan, Huiyao; Hu, Wenhui; Yang, Zhongjin; Wu, Nannan published a patent.Recommanded Product: 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one The title of the patent was Azaindoles and their application as antitumor drugs. And the patent contained the following:

The invention provides azaindoles and its application, which can effectively inhibit the phosphorylation of SMAD3, and has good antitumor activity in the tumor model induced by LCC in rats. The invention provides azaindole or its pharmaceutically acceptable salt or stereoisomer or prodrug mol. as shown in formula I, wherein D is selected from C and N; and R2 does not exist when D is N; A and B are independently selected from N and CR3; R1 is selected from H, C1-C6 alkyl, C6-C10 aryl, C3-C8 cycloalkyl, halogen, CN; R2 selected from: H, C1-C6 alkyl; each R3 is independently selected from H, C1-C6 alkyl, halogen, CN; R4 is selected from carbonyl compounds; R5, R5a, R5b = H, halogen, CN, C1-C6 alkyl, C3-C8 cycloalkyl. For example, compound II was prepared in a multi-step synthesis. The title compound can be used as a pharmaceutical composition for the prevention and/or treatment of cancer. The experimental process involved the reaction of 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one(cas: 1009104-85-1).Recommanded Product: 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one

The Article related to azaindole anticancer agent elimination reaction amidation substitution, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 6, 2021, Yu, Hongtao; Hu, Qi; Huang, Jing; Wang, Tingliang; Hou, Ningke; Zhang, Lijing; Zhang, Wenyi; Tan, Qiaozhu published a patent.Synthetic Route of 1378839-26-9 The title of the patent was Preparation of heterocyclic derivatives as 3C like protease inhibitors. And the patent contained the following:

The invention relates to the preparation of heterocyclic derivatives with general formula I as 3C like protease inhibitors, where Ar = Ph or 6-membered heteroaryl; ring A = 9 or 10-membered heteroaryl, wherein: V1 , V2, V3, and V4 = not present, CH or N; and at most one of V1, V2, V3, and V4 may not exist; when one of W1, W2, W3, and W4 does not exist, then V1, V2, V3, and None of V4 can be absent; W1, W2, W3, and W4 = not present, CH or N; at most one of W1, W2, W3, and W4 can be absent; at least one of W1, W2, W3, and W4 must be N; X = absent, NRa or NRa(CRbRc)a; Y = absent, C3-C12 carbocyclyl, 3-12 membered heterocyclic group, or 5-10 membered heteroaryl; Z = absent, NRd, (CReRf)bNRd or C(=O)NRd(CRgRh)c; Ra and Rd = hydrogen or C1-C4 alkyl; Rb, Rc, Re and Rf = hydrogen or substituted C1-C4 alkyl; Rg and Rh = hydrogen or substituted C1-C4 alkyl; Ri and Rj = hydrogen or C1-C4 alkyl; a, b and c = 1, 2, 3 or 4; R1, R2. And R3 = halogen, cyano, C1-C6 alkane Group, C2-C6 alkenyl, C1-C6 alkoxy, C(=O)(C1-C6 alkyl), C(=O)NRpRq, NRpRq, NRpC(=O)Rs, NRpC(=O)ORs , NRpC(=O)NRqRr, NRpS(=O)wRs, NO2, NO2+, NH(=O)OH, ORs, OC(=O)Rs, OC(=O)ORs, OC(=O)NRpRq, S(=O)wRs, S(=O)wNRpRq, SO3, C3-C12 carbocyclic group, 3-12 membered heterocyclic group, Ph, 5-10 membered heteroaryl; Rp, Rq and Rr = hydrogen, C1-C4 alkyl or C3-C6 cycloalkyl; Rs = hydrogen, C1-C4 alkyl or C3-C6 cycloalkyl; m = 0 For example, 5-bromo-2-((1-(5-hydroxyisoquinoline-4-carbonyl)piperidin-3-yl)amino)-N-methyl-3-nitrobenzamide was prepared by a multi-step reaction. The title compounds have good inhibitory effect on 3C like protease and can be used to treat SARS-COV-2 infection. The experimental process involved the reaction of 7-Hydroxyisoquinoline-4-carboxylic acid(cas: 1378839-26-9).Synthetic Route of 1378839-26-9

The Article related to amidation coupling hydrolysis preparation piperazine isoquinoline treatment human coronavirus, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Synthetic Route of 1378839-26-9

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On November 30, 1989, Volovenko, Yu. M.; Litvinenko, S. V.; Babichev, F. S. published an article.Computed Properties of 58142-46-4 The title of the article was Annulation of benzoindolizine rings to quinoxaline nucleus. And the article contained the following:

Quinoxalineacetonitriles I (R3 = Me, Ph, or 4-MeC6H4) react with isoquinolines II (R1 = H, R2 = H, NO2; R1 = Br, R2 = NO2) 2-4 h in DMF at 160° or reflux to give quant. benzindolizinoquinoxalines III. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Computed Properties of 58142-46-4

The Article related to benzindolizinoquinoxalinecarbonitrile, indolizinoquinoxaline benz, quinoxaline benzindolizino, isoquinoline quinoxalineacetonitrile reaction, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Computed Properties of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 31, 1992, Werra, W.; Heber, D. published an article.Product Details of 58142-46-4 The title of the article was 1H and 13C NMR studies of substituted isoquinolinium derivatives in different solvents. And the article contained the following:

1H and 13C NMR data for 1-cyano-, 4-cyano-, 4-bromo- and 4-bromo-5-nitro-substituted isoquinolines, isoquinoline N-oxides and N-methoxy and N-Et salts in different solvents are reported. The substituent chem. shifts are discussed with regard to the reactivity of the N-methoxy compounds in the presence of nucleophilic reagents. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Product Details of 58142-46-4

The Article related to nmr isoquinolinium compound solvent effect, Physical Organic Chemistry: Resonance Spectra (Electron Spin, Nuclear Magnetic and Fourier Transform Nuclear Magnetic, Quadrupole, etc.) and other aspects.Product Details of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On February 28, 2008, Lautens, Mark; Yuen, Josephine; Fang, Yuanqing published a patent.Application of 1009104-85-1 The title of the patent was Process for preparation of pyrrole derivatives. And the patent contained the following:

The present invention pertains to processes for the chem. synthesis of pyrrole derivatives, particularly azaindole and thienopyrrole compounds that are substituted at the 2-position of the azaindole or thienopyrrole ring. For example, to a mixture of 3-(2,2-dibromoethenyl)-N-methyl-2-pyridinamine (preparation given), phenylboronic acid, and K3PO4•H2O under argon was added a solution of Pd(OAc)2 and S-Phos in toluene. The reaction was heated to 100 °C for 2 h., then cooled to room temperature, worked-up with saturated NaHCO3 solution, extracted with Et2O, dried over Na2SO4, and concentrated in vacuo. The crude material was purified using chromatog. eluting with 25 % EtOAc/hexane to yield the product, 1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridine, as a white solid in 84% yield. 1-Methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridine obtained above can be used for the preparation of com. important azaindole compounds as pharmaceutical agents. The experimental process involved the reaction of 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one(cas: 1009104-85-1).Application of 1009104-85-1

The Article related to preparation pyrrolopyridine thienopyrrole azaindole, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Application of 1009104-85-1

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On November 5, 2015, Wu, Lingyun; Yao, Yuanshan; Chen, Zhaoguo; Chen, Shuhui published a patent.SDS of cas: 58142-46-4 The title of the patent was Preparation of isoquinolinesulfonyl derivatives as Rho kinase inhibitors. And the patent contained the following:

The invention relates to isoquinolinesulfonyl derivatives (e.g., I) and their pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical preparations comprising them, and their use as Rho kinase inhibitors. For instance, the invention compound I was prepared and gave a ROCK kinase inhibition IC50 value of <0.1μM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).SDS of cas: 58142-46-4

The Article related to isoquinolinesulfonyl preparation rho kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.SDS of cas: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On November 25, 2015, Wu, Lingyun; Yao, Yuanshan; Chen, Zhaoguo; Chen, Shuhui published a patent.Quality Control of 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation of isoquinolinesulfonyl derivatives as Rho kinase inhibitors. And the patent contained the following:

The invention relates to isoquinolinesulfonyl derivatives (e.g., I) and their pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical preparations comprising them, and their use as Rho kinase inhibitors. For instance, the invention compound I was prepared and gave a ROCK kinase inhibition IC50 value of <0.1μM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Quality Control of 4-Bromo-5-nitroisoquinoline

The Article related to isoquinolinesulfonyl preparation rho kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Quality Control of 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem